[Sensitivity to change and minimally important difference of the Spanish version of the life-satisfaction questionnaire LISAT-8 in male patients with erectile dysfunction]

Med Clin (Barc). 2005 Feb 12;124(5):165-71. doi: 10.1157/13071490.
[Article in Spanish]

Abstract

Background and objective: We determined the sensitivity to change and minimally important difference (MID) of the Spanish version of the life-satisfaction check list LISAT-8.

Patients and method: We included a random sample obtained from an open, naturalistic, prospective and multicenter study, which assessed the effectiveness of sildenafil as erectile dysfunction (ED) therapy. A total of 537 patients, males older than 18 years, with ED and > active sexual desire, received flexible and at demand doses of sildenafil for 10 weeks. IIEF and LISAT-8 questionnaires were used. MID was determined from the patient's classification according to change in erectile function domain of the IIEF after treatment as follows: no change (< 5 pts), small change (6 to 10 pts), moderate change (11 to 15 pts) and big change (> 15 pts).

Results: Sildenafil significantly modified the baseline punctuation of the LISAT 8 from a crude value of 30.2 (5.9) pts (mean [standard deviation]), at baseline, to 34.7 (5.6) pts after treatment., and from 55.4% (14.7%) to 66.8% (14.3%) in standardized punctuation (p < 0.0001 in both cases). Sildenafil responders showed a response increase of the total punctuation which was significantly higher than non-responders: 12.5% versus 4.3% (p < 0.001). MID was 3.2 pts as crude punctuation, and 8.1% in normalized score. Statistically significant correlations were found between changes in LISAT-8 and changes in IIEF.

Conclusions: The Spanish version of the LISAT-8 showed to be responsive to change in male ED patients. Meaningful MID was 3.1 pts (crude) and 8.1% (normalized).

Publication types

  • Validation Study

MeSH terms

  • Erectile Dysfunction / drug therapy*
  • Humans
  • Language
  • Male
  • Middle Aged
  • Phosphodiesterase Inhibitors / therapeutic use
  • Piperazines / therapeutic use
  • Purines
  • Quality of Life*
  • Sildenafil Citrate
  • Spain
  • Sulfones
  • Surveys and Questionnaires*

Substances

  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Sildenafil Citrate